

# PRODUCT INFORMATION



## PND1186

Item No. 17668

**CAS Registry No.:** 1061353-68-1  
**Formal Name:** 2-[[2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyridinyl]amino]-N-methyl-benzamide

**Synonyms:** SR 2516, VS-4718

**MF:** C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>

**FW:** 501.5


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 294 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

PND1186 is supplied as a crystalline solid. A stock solution may be made by dissolving the PND1186 in the solvent of choice. PND1186 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of PND1186 in these solvents is approximately 30, 5, and 10 mg/ml, respectively.

PND1186 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PND1186 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. PND1186 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

PND1186 is a potent reversible focal adhesion kinase (FAK) inhibitor with an IC<sub>50</sub> value of 1.5 nM against the recombinant enzyme and 100 nM in breast carcinoma cells.<sup>1</sup> It promotes 4T1 breast carcinoma and ID8 ovarian carcinoma cell apoptosis when grown in anchorage-independent 3D cultures but had limited efficacy in 2D cultures. It is orally bioavailable, reducing orthotopic breast cancer tumor growth in mouse models.<sup>2</sup>

## References

1. Tanjoni, I., Walsh, C., Uryu, S., *et al.* PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. *Cancer Biol. Ther.* **9(10)**, 764-777 (2010).
2. Walsh, C., Tanjoni, I., Uryu, S. *et al.* Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. *Cancer Biol. Ther.* **9(10)**, 778-790 (2010).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2016

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM